Nasdaq:NRIX
Nurix Therapeutics, Inc.
An AI-driven biotechnology company accelerating the discovery of novel therapeutics for serious diseases with a strong cash position but facing high burn rates.
Key Metrics
Investment Thesis
Bull Case
Nurix offers exposure to the high-growth intersection of artificial intelligence and biotechnology with a proprietary platform that could disrupt traditional drug discovery timelines. The company's revenue nearly doubled in 2025 compared to the prior year, suggesting growing commercial traction or successful licensing milestones. A strong balance sheet with over $247 million in cash provides a runway to navigate the costly early phases of clinical development without immediate dilution pressure.
Bear Case
The widening net loss from $193.6 million in 2024 to $264.5 million in 2025 signals deteriorating financial efficiency and potential unsustainable burn rates for a pre-revenue biotech firm. Operating expenses of $369.6 million vastly exceed gross profit, creating a negative operating profit margin that has deepened year-over-year. Investors may face significant downside risk if the company fails to secure additional funding or achieve clinical success in its current pipeline.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biotechnology company leveraging artificial intelligence to discover and develop novel small molecules for treating serious diseases. The firm operates primarily within the United States pharmaceutical market, focusing on oncology, immunology, and other therapeutic areas through its proprietary AI-driven drug discovery platform. Key products are in various stages of clinical development, supported by significant R&D investments totaling over $316 million in the latest fiscal year.
Analysis
Management Discussion
Despite a 119% revenue increase year-over-year from $54.5 million in 2024 to $84.0 million in 2025, the company's net loss widened to $264.5 million, driven by elevated operating expenses and substantial research and development spending of $316.9 million. The positive cash flow from financing of $238.6 million highlights ongoing capital raising efforts necessary to sustain operations while advancing its clinical pipeline. Current assets remain robust at $606.8 million, largely due to a strong cash balance that exceeds total liabilities.
Industry Overview
The global biotechnology industry is characterized by high capital intensity and regulatory hurdles, with AI-driven discovery becoming a key differentiator for emerging players. Companies in this sector often operate at a loss during development phases while awaiting approval from agencies like the FDA to generate commercial revenue. Market dynamics favor firms that can successfully translate novel technologies into approved therapies that address unmet medical needs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $38.6M | $77.0M | $54.5M | $84.0M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $38.6M | $77.0M | $54.5M | $84.0M |
| Operating Expenses | $222.5M | $232.1M | $267.6M | $369.6M |
| Operating Income | $-183.9M | $-155.1M | $-213.0M | $-285.7M |
| R&D | $184.5M | $189.1M | $221.6M | $316.9M |
| G&A | $38.0M | $42.9M | $45.9M | $52.7M |
| Stock-Based Comp | $28.1M | $33.7M | $33.9M | $38.0M |
| D&A | $5.3M | $7.5M | $9.3M | $8.7M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $3.5M | $11.1M | $19.7M | $22.0M |
| Pre-Tax Income | $-180.4M | $-143.9M | $-193.3M | $-263.7M |
| Income Tax | $0 | $0 | $270.0K | $760.0K |
| Continuing Ops | $-180.4M | $-143.9M | $-193.6M | $-264.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-180.4M | $-143.9M | $-193.6M | $-264.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-180.4M | $-143.9M | $-193.6M | $-264.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $318.4M | $295.5M | $619.4M | $606.8M |
| Cash & Equivalents | $64.5M | $54.6M | $110.0M | $247.0M |
| Marketable Securities | $244.7M | — | — | — |
| Prepaid Expenses | $9.3M | $7.6M | $9.8M | $13.9M |
| Other Current Assets | $0 | $233.3M | $499.6M | $346.0M |
| Long-Term Assets | $98.3M | $60.1M | $50.0M | $81.3M |
| PP&E (Net) | $17.2M | $16.8M | $17.8M | $22.5M |
| Operating Leases | $12.3M | $31.1M | $28.1M | $50.5M |
| LT Investments | $63.9M | — | — | — |
| Other LT Assets | $4.9M | $12.1M | $4.1M | $8.3M |
| Total Assets | $416.8M | $355.6M | $669.3M | $688.1M |
| Current Liabilities | $70.7M | $87.0M | $95.9M | $86.5M |
| Accounts Payable | $5.1M | $6.4M | $11.5M | $11.2M |
| Current Leases | $5.5M | $7.5M | $8.0M | $2.8M |
| Deferred Revenue | $37.6M | $48.1M | $38.4M | $17.6M |
| Other Current Liab | $22.4M | $25.0M | $38.0M | $54.9M |
| Long-Term Liabilities | $42.4M | $68.1M | $46.5M | $62.9M |
| LT Operating Leases | $6.4M | $23.1M | $20.3M | $52.9M |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $113.1M | $155.1M | $142.3M | $149.4M |
| Shareholders' Equity | $303.7M | $200.5M | $527.0M | $538.7M |
| Retained Earnings | $-401.3M | $-545.2M | $-738.8M | $-1.00B |
| AOCI | $-4.3M | $-655.0K | $150.0K | $105.0K |
| Total L&E | $416.8M | $355.6M | $669.3M | $688.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-180.4M | $-143.9M | $-193.6M | $-264.5M |
| Non-Cash Adjustments | $49.4M | $46.7M | $38.5M | $34.1M |
| Working Capital Changes | $-28.8M | $15.8M | $-17.5M | $-19.1M |
| Cash from Operations | $-159.8M | $-81.4M | $-172.6M | $-249.5M |
| Capital Expenditures | $12.2M | $8.4M | $9.3M | $14.0M |
| Cash from Investing | $27.2M | $68.3M | $-257.7M | $147.9M |
| Cash from Financing | $117.2M | $3.2M | $485.7M | $238.6M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-15.4M | $-9.8M | $55.4M | $137.0M |
| Beginning Cash | $80.8M | $65.4M | $55.5M | $110.9M |
| Ending Cash | $65.4M | $55.5M | $110.9M | $247.9M |
Frequently Asked Questions
How does Nurix Therapeutics, Inc. make money?
The company's revenue is generated primarily from product sales and licensing agreements related to its small molecule drug candidates. Financials indicate a heavy reliance on research and development activities, with operating expenses significantly outpacing gross profit due to the early-stage nature of its pipeline assets.
What are the main risks for NRIX?
The company reports a net loss of $264.5 million in 2025, indicating high cash burn that could deplete resources if new revenue streams do not materialize quickly. Clinical trial failures for its drug candidates would result in significant write-downs and potential loss of investor confidence. Regulatory approval processes for novel therapeutics are lengthy and uncertain, posing a risk to future commercialization timelines. Dependence on external funding sources remains critical given the current operating deficit.
What is NRIX's competitive advantage?
Nurix possesses a unique proprietary artificial intelligence platform that reduces the time and cost required for traditional drug discovery processes. The company maintains a substantial cash reserve of approximately $247 million, providing flexibility to advance multiple clinical programs simultaneously. Its focus on small molecules offers potential advantages in manufacturing scalability compared to large biologic therapies.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.